Gemcitabine Single-Agent Dosing for Metastatic Breast Cancer
For metastatic breast cancer, gemcitabine as a single agent should be dosed at 1250 mg/m² intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle, with no dose adjustment required for mild to moderate renal impairment. 1
Standard Dosing Regimen
The FDA-approved dosing for single-agent gemcitabine in metastatic breast cancer is:
- 1250 mg/m² IV over 30 minutes
- Days 1 and 8 of each 21-day cycle 1
This is the established regimen when gemcitabine is used as monotherapy, though it's important to note that NCCN guidelines classify gemcitabine as a "preferred" single agent for metastatic breast cancer, particularly in patients who have been previously treated with anthracyclines and taxanes 2.
Dose Modifications for Myelosuppression
On Day 1 of treatment:
- Hold dose if ANC <1500 × 10⁶/L OR platelets <100,000 × 10⁶/L 1
On Day 8 of treatment:
- ANC ≥1200 AND platelets >75,000: Give full dose
- ANC 1000-1199 OR platelets 50,000-75,000: Give 75% of dose
- ANC 700-999 AND platelets ≥50,000: Give 50% of dose
- ANC <700 OR platelets <50,000: Hold dose 1
Renal Impairment Considerations
No dose adjustment is necessary for renal impairment. A phase I pharmacokinetic study specifically evaluated gemcitabine in patients with renal dysfunction and found no significant relationship between gemcitabine clearance and renal function indices (EDTA-Cr clearance, p=0.797) 3. This study included patients with creatinine clearances as low as 30 mL/min and demonstrated that mild to moderate renal insufficiency does not significantly impact gemcitabine pharmacokinetics 3.
The FDA label does not specify dose reductions for renal impairment 1, which aligns with the pharmacokinetic data showing gemcitabine is primarily metabolized intracellularly rather than renally excreted.
Clinical Context and Efficacy
Single-agent gemcitabine demonstrates:
- Overall response rate: 26-30% in metastatic breast cancer 4, 5
- Well-tolerated toxicity profile with dose-limiting toxicity primarily being neutropenia 6
- Grade 3-4 neutropenia occurs in approximately 19-25% of patients 1, 6
Important Safety Monitoring
Monitor complete blood counts before each dose, as 94% of protocol-defined doses were administered in clinical trials, with only 14% requiring dose reduction 6. The most common adverse reactions (≥20%) include nausea/vomiting, anemia, elevated transaminases, neutropenia, and thrombocytopenia 1.
Critical pitfall: While gemcitabine is generally well-tolerated in renal impairment, be vigilant for rare but serious complications including hemolytic uremic syndrome (HUS), which can occur even with weekly dosing schedules after cumulative doses 7. Watch for microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury.